COMP <GO>
KRYS vs RGEN // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Krystal Biotech Inc. (NASDAQ) VS. Repligen Corporation (NASDAQ) • 15-METRIC TALLY: KRYS 8
— RGEN 2
■ METRIC PARITY
LAST: $295.90 (-10.95%) • MKT CAP: $9.84B
options-implied-move
—
LAST: $172.95 (-2.25%) • MKT CAP: $10.03B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. RGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | RGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 2.30% | +14.20 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.4x | 95.0x | -41.60 | KRYS | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 0.88% | +1.09 | KRYS | /fcf-yield <GO> |
| Operating Margin | 41.50% | 1.80% | +39.70 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 1.60% | +51.00 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 33.90% | -3.30% | +37.20 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.31 | +16.69 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 48.0 | +5.80 | KRYS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.04 | -0.13 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.84B | $10.03B | -$195.8M | RGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | RGEN REV | KRYS GROSS % | RGEN GROSS % | KRYS FCF | RGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $154.5M | — | — | $188.9M | $93.9M |
| FY 2024 | $290.5M | $98.3M | — | — | $119.2M | $149.7M |
| FY 2023 | $50.7M | $133.6M | — | — | -$91.1M | $113.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
RGEN // BETA 1.04